Lifeline offered for patients with dangerous Tumor-Related low blood sugar

This program provides access to an investigational drug called ersodetug for people with tumor-associated hyperinsulinism who suffer from severe, uncontrolled low blood sugar and cannot participate in regular clinical trials. It is designed for patients whose condition is not adequately managed with current standard treatments. The goal is to help control dangerous hypoglycemia in this specific patient population through physician-supervised treatment.